Autophagy in malignant transformation and cancer progression

Lorenzo Galluzzi1,2,3,4*,†, Federico Pietrocola1,2,3†, José Manuel Bravo-San Pedro1,2,3†, Ravi K Amaravadi5, Eric H Baehrecke6, Francesco Ceconi7,8, Patrice Codogno4,9,10,11, Jayanta Debnath12, David A Gewirtz13, Vassiliki Karantza14, Alec Kimmelman15, Sharad Kumar16, Beth Levine17,18,19, Maria Chiara Maiuri1,2,3, Seamus J Martin20, Josef Penninger21, Mauro Piacentini‡,‡, Seamus J Martin20, Josef Penninger21, Mauro Piacentini‡,‡, Andrew M Thorburn27, Guillermo Velasco28,29, Kevin M Ryan30,‡ & Guido Kroemer1,2,4,31,32,‡

Abstract

Autophagy plays a key role in the maintenance of cellular homeostasis. In healthy cells, such a homeostatic activity constitutes a robust barrier against malignant transformation. Accordingly, many oncoproteins inhibit, and several oncosuppressor proteins promote, autophagy. Moreover, autophagy is required for optimal anticancer immunosurveillance. In neoplastic cells, however, autophagic responses constitute a means to cope with intracellular and environmental stress, thus favoring tumor progression. This implies that at least in some cases, oncogenesis proceeds along with a temporary inhibition of autophagy or a gain of molecular functions that antagonize its oncosuppressive activity. Here, we discuss the differential impact of autophagy on distinct phases of tumorigenesis and the implications of this concept for the use of autophagy modulators in cancer therapy.

Keywords adaptive stress responses; Beclin 1; inflammation; KRAS; mitophagy

DOI 10.15252/embj.201490784 | Received 12 December 2014 | Revised 14 January 2015 | Accepted 16 January 2015
Introduction

Macroautophagy (herein referred to as autophagy) is a mechanism that mediates the sequestration of intracellular entities within double-membraned vesicles, so-called autophagosomes, and their delivery to lysosomes for bulk degradation (He & Klionsky, 2009). Autophagosomes derive from so-called phagophores, membranous structures also known as ‘isolation membranes’ whose precise origin remains a matter of debate (Lamb et al, 2013). Indeed, the plasma membrane, endoplasmic reticulum (ER), Golgi apparatus, ER-Golgi intermediate compartment (ERGIC), and mitochondria have all been indicated as possible sources for phagophores (Lamb et al, 2013). Upon closure, autophagosomes fuse with lysosomes, forming so-called autolysosomes, and their cargo is exposed to the catalytic activity of lysosomal hydrolases (Mizushima & Komatsu, 2011). The degradation products of the autophagosomal cargo, which includes sugars, nucleosides/nucleotides, amino acids and fatty acids, can be transported back to the cytoplasm and presumably re-enter cellular metabolism (Fig 1) (Rabinowitz & White, 2010; Galluzzi et al, 2013). Of note, the molecular machinery that mediates autophagy is evolutionarily conserved, and several components thereof have initially been characterized in yeast (He & Klionsky, 2009).

In physiological scenarios, autophagy proceeds at basal levels, ensuring the continuous removal of superfluous, ectopic or damaged (and hence potentially dangerous) entities, including organelles and/or portions thereof (Green et al, 2011). Baseline autophagy mediates a key homeostatic function, constantly operating as an intracellular quality control system (Mizushima et al, 2008; Green et al, 2011). Moreover, the autophagic flux can be upregulated in response to a wide panel of stimuli, including (but not limited to) nutritional, metabolic, oxidative, pathogenic, genotoxic and proteotoxic cues (Kroemer et al, 2010). Often, stimulus-induced autophagy underlies and sustains an adaptive response to stress with cytoprotective functions (Kroemer et al, 2010; Mizushima & Komatsu, 2011). Indeed, the pharmacological or genetic inhibition of autophagy generally limits the ability of cells to cope with stress and restore homeostasis (Mizushima et al, 2008; Kroemer et al, 2010). This said, regulated instances of cell death that causally depend on the autophagic machinery have been described (Denton et al, 2009; Denton et al, 2012b; Liu et al, 2013b; Galluzzi et al, 2015). The detailed discussion of such forms of autophagic cell death, however, is beyond the scope of this review.

Autophagy is tightly regulated. The best characterized repressor of autophagic responses is mechanistic target of rapamycin (MTOR) complex 1 (MTORC1) (Laplante & Sabatini, 2012). Thus, several inducers of autophagy operate by trigger signal transduction cascades that result in the inhibition of MTORC1 (Inoki et al, 2012). Among other effects, this allows for the activation of several proteins that are crucial for the initiation of autophagic responses, such as unc-51-like autophagy-activating kinase 1 (ULK1, the mammalian ortholog of yeast Atg1) and autophagy-related 13 (ATG13) (Hosokawa et al, 2009; Nazio et al, 2013). A major inhibitor of MTORC1 is protein kinase, AMP-activated (PRKA, best known as AMPK), which is sensitive to declining ATP/AMP ratios (Mihaylova & Shaw, 2011). Besides inhibiting the catalytic activity of MTORC1, AMPK directly stimulates autophagy by phosphorylating ULK1 as well as phosphatidylinositol 3-kinase, catalytic subunit type 3 (PI3KC3, best known as VPS34) and Beclin 1 (BECN1, the mammalian ortholog of yeast Atg6), two components of a multiprotein complex that produces a lipid that is essential for the biogenesis of autophagosomes, namely phosphatidylinositol 3-phosphate (Egan et al, 2011; Zhao & Klionsky, 2011; Kim et al, 2013). Autophagy also critically relies on two ubiquitin-like conjugation systems, both of which involve ATG7 (Mizushima, 2007). These systems catalyze the covalent linkage of ATG5 to ATG12 and ATG16-like 1 (ATG16L1), and that of phosphatidylinethanolamine to proteins of the microtubule-associated protein 1 light chain 3 (MAP1LC3, best known as LC3) family, including MAP1LC3B (LC3B, the mammalian ortholog of yeast Atg8) (Mizushima, 2007). A detailed discussion of additional factors that are involved in the control and execution of autophagic responses can be found in Boya et al (2013).

Importantly, autophagosomes can either take up intracellular material in a relatively non-selective manner or deliver very specific portions of the cytoplasm to degradation, mainly depending on the initiating stimulus (Weidberg et al, 2011; Stolz et al, 2014). Thus, while non-selective forms of autophagy normally develop in response to cell-wide alterations, most often of a metabolic nature, highly targeted autophagic responses follow specific perturbations of intracellular homeostasis, such as the accumulation of permeabilized mitochondria (mitophagy), the formation of protein aggregates (aggrephagy), and pathogen invasion (xenophagy) (Okamoto, 2014; Randow & Youle, 2014). Several receptors participate in the selective recognition and recruitment of autophagosomal cargoes in the course of targeted autophagic responses (Rogov et al, 2014; Stolz et al, 2014). The autophagy receptor best characterized to date, that is, sequestosome 1 (SQSTM1, best known as p62), recruits ubiquitinated proteins to autophagosomes by virtue of an ubiquitin-associated (UBA) and a LC3-binding domain (Pankiv et al, 2007).

Owing to its key role in the preservation of intracellular homeostasis, autophagy constitutes a barrier against various degenerative processes that may affect healthy cells, including malignant transformation. Thus, autophagy mediates oncosuppressive effects. Accordingly, proteins with bona fide oncogenic potential inhibit autophagy, while many proteins that prevent malignant transformation stimulate autophagic responses (Morselli et al, 2011). Moreover, autophagy is involved in several aspects of anticancer immunosurveillance, that is, the process whereby the immune system constantly eliminates potentially tumorigenic cells before they establish malignant lesions (Ma et al, 2013). However, autophagy also sustains the survival and proliferation of neoplastic cells exposed to intracellular and environmental stress, hence supporting tumor growth, invasion and metastatic dissemination, at least in some settings (Kroemer et al, 2010; Guo et al, 2013b). Here, we discuss the molecular and cellular mechanisms accounting for the differential impact of autophagy on malignant transformation and tumor progression.

Autophagy and malignant transformation

In various murine models, defects in the autophagic machinery caused by the whole-body or tissue-specific, heterozygous or homozygous knockout of essential autophagy genes accelerate oncogenesis. For instance, Becn1−/− mice (Becn1−/− animals are not viable) spontaneously develop various malignancies, including lymphomas as well as lung and liver carcinomas (Liang et al, 1999; Qu et al,
2003; Yue et al., 2003; Mortensen et al., 2011), and are more susceptible to parity-associated and Wnt1-driven mammary carcinogenesis than their wild-type counterparts (Cicchini et al., 2014). Similarly, mice lacking one copy of the gene coding for the BECN1 interactor autophagy/beclin-1 regulator 1 (AMBRA1) also exhibit a higher rate of spontaneous tumorigenesis than their wild-type littermates (Cianfanelli et al., 2015). Mice bearing a systemic mosaic deletion of Atg5 or a liver-specific knockout of Atg7 spontaneously develop...
benign hepatic neoplasms more frequently than their wild-type counterparts (Takamura et al., 2011). Moreover, carcinogen-induced fibrosarcomas appear at an accelerated pace in autophagy-deficient Atg4c−/− mice (Marino et al., 2007), as do KRASG12V-driven and BRAFV600E-driven lung carcinomas in mice bearing lung-restricted Atg5 or Atg7 deletions, respectively (Strohecker et al., 2013; Rao et al., 2014). The pancreas-specific knockout of Atg5 or Atg7 also precipitates the emergence of KRASG12V-driven pre-malignant pancreatic lesions (Rosenfeldt et al., 2013; Yang et al., 2014).

Several mechanisms can explain, at least in part, the oncosuppressive functions of autophagy. Proficient autophagic responses may suppress the accumulation of genetic and genomic defects that accompanies malignant transformation, through a variety of mechanisms. Reactive oxygen species (ROS) are highly genotoxic, and autophagy prevents their overproduction by removing dysfunctional mitochondria (Green et al., 2011; Takahashi et al., 2013) as well as redox-active aggregates of ubiquitinated proteins (Komatsu et al., 2007; Mathew et al., 2009). In addition, autophagic responses have been involved in the disposal of micronuclei arising upon perturbation of the cell cycle (Rello-Varona et al., 2012), in the degradation of retrotransposing RNAs (Guo et al., 2014), as well as in the control of the levels of ras homolog family member A (RHOA), a small GTPase involved in cytokinesis (Belaid et al., 2013). Finally, various components of the autophagic machinery appear to be required for cells to mount adequate responses to genotoxic stress (Karantza-Wadsworth et al., 2007; Mathew et al., 2007; Park et al., 2014). This said, the precise mechanisms underlying such genome-stabilizing effects remain elusive, implying that the impact of autophagy on DNA-damage responses may be indirect. Further investigation is required to shed light on this possibility.

Autophagy is intimately implicated in the maintenance of physiological metabolic homeostasis (Galluzzi et al., 2014; Kenific & Debnath, 2015). Malignant transformation generally occurs along with a shift from a predominantly catabolic consumption of glycolysis-derived pyruvate by oxidative phosphorylation to a metabolic pattern in which: (1) glucose uptake is significantly augmented to sustain anabolic reactions and antioxidant defenses, (2) mitochondrial respiration remains high to satisfy increased energy demands; and (3) several amino acids, including glutamine and serine, become essential as a means to cope with exacerbated metabolic functions (Hanahan & Weinberg, 2011; Galluzzi et al., 2013). Autophagy preserves optimal bioenergetic functions by ensuring the removal of dysfunctional mitochondria (Green et al., 2011), de facto counteracting the metabolic rewiring that accompanies malignant transformation. Moreover, the autophagic degradation of p62 participates in a feedback circuitry that regulates MTORC1 activation in response to nutrient availability (Linares et al., 2013; Valencia et al., 2014).

Autophagy appears to ensure the maintenance of normal stem cells. This is particularly relevant for hematological malignancies, which are normally characterized by changes in proliferation or differentiation potential that alter the delicate equilibrium between toti-, pluri- and unipotent precursors in the bone marrow (Greim et al., 2014). The ablation of Atg7 in murine hematopoietic stem cells (HSCs) has been shown to disrupt tissue architecture, eventually resulting in the expansion of a population of bone marrow progenitor cells with neoplastic features (Mortensen et al., 2011). Along similar lines, the tissue-specific deletion of the gene coding for the ULK1 interactor RB1-inducible coiled-coil 1 (RB1CC1, best known as FIP200) alters the fetal HSC compartment in mice, resulting in severe anemia and perinatal lethality (Liu et al., 2010). Interestingly, murine Rb1cc1−/− HSCs do not exhibit increased rates of apoptosis, but an accrued proliferative capacity (Liu et al., 2010). The deletion of Rb1cc1 in murine neuronal stem cells (NSCs) also causes a functional impairment that compromises postnatal neuronal differentiation (Wang et al., 2013). However, this effect appears to stem from the failure of murine Rb1cc1−/− HNCs to control redox homeostasis, resulting in the activation of a tumor protein p53 (TP53)-dependent apoptotic response (Wang et al., 2013). Finally, Becn1−/− mice display an expansion of progenitor-like mammary epithelial cells (Cicchini et al., 2014). Of note, autophagy also appears to be required for the preservation of normal stem cell compartments in the human system. Indeed, human hematopoietic, dermal, and epidermal stem cells transfected with a short-hairpin RNA (shRNA) specific for ATG5 lose their ability to self-renew while differentiating into neutrophils, fibroblasts, and keratinocytes, respectively (Salemi et al., 2012).

It has been proposed that autophagy contributes to oncogene-induced cell death or oncogene-induced senescence, two fundamental oncosuppressive mechanisms. The activation of various oncogenes imposes indeed a significant stress on healthy cells, a situation that is normally aborted through the execution of a cell death program (Elgendy et al., 2011), or upon the establishment of permanent proliferative arrest (cell senescence) that engages the innate arm of the immune system (Iannello et al., 2013). The partial depletion of ATG5, ATG7 or Becn1 limited the demise of human ovarian cancer cells pharmacologically stimulated to express HRASG12V from an inducible construct (Elgendy et al., 2011). Similarly, shRNAs specific for ATG5 or ATG7 prevented oncogene-induced senescence in primary human melanocytes or human diploid fibroblasts (HDFs) expressing BRAFV600E or HRASG12V (Young et al., 2009; Liu et al., 2013a). Accordingly, the overexpression of the ULK1 homolog ULK3 was sufficient to limit the proliferative potential of HDFs while promoting autophagy (Young et al., 2009). Moreover, both pharmacological inhibitors of autophagy and small-interfering RNAs targeting ATG5, ATG7 or Becn1 prevented spontaneous senescence in HDFs while preventing the degradation of an endogenous, dominant-negative TP53 variant (Horikawa et al., 2014). Finally, ectopic ATG5 expression reduced the colony-forming ability of melanoma cell lines normally characterized by low ATG5 levels, an effect that could be reproduced by the administration of autophagy inducers (Liu et al., 2013a). Apparently at odds with these results, HRASG12V fails to induce senescence in mouse embryonic fibroblasts (MEFs) lacking transformation-related protein 53 binding protein 2 (Trp53bp2), correlating with the stabilization of Atg5/Atg12 complexes and consequent upregulation of the autophagic flux. In line with this notion, ectopic expression of Atg5 prevented Trp53bp2-sufficient MEFs from entering senescence upon overexpression of HRASG12V (Wang et al., 2012b). Thus, while in some cells autophagy appears to inhibit malignant transformation by favoring oncogene-induced senescence, this may not be a general mechanism of autophagy-mediated oncosuppression.

It has been suggested that autophagy is involved in the degradation of oncogenic proteins, including mutant (but not wild-type) TP53 (Rodriguez et al., 2012; Choudhury et al., 2013; Garufi et al., 2015).
Published online: February 23, 2015

Lorenzo Galluzzi et al  Autophagic responses and cancer

The EMBO Journal

2014), p62 (Duran et al, 2008; Mathew et al, 2009; Ling et al, 2012), PML-RARA (Isakson et al, 2010; Wang et al, 2011), and BCR-ABL1 (Goussietis et al, 2012). Mutant TP53 often accumulates in neoplastic cells and operates as a dominant-negative factor, thereby interfering with the oncogenicity of the wild-type protein (de Vries et al, 2002). Cancer cells depleted of ULK1, BECN1 or ATG5 tend to accumulate increased amounts of mutant TP53, whereas the transgene-driven overexpression of BECN1 or ATG5 results in mutant TP53 depletion (Choudhury et al, 2013). Such an autophagy-dependent degradation of mutant TP53 would therefore restore the ability of wild-type TP53 to inhibit malignant transformation, at least in some settings. It is worth noting that both ATG5 and ATG7 have been involved in the regulation of TP53-dependent adaptive responses to stress (Lee et al, 2012; Salemi et al, 2012). However, this activity appears to be independent of autophagy, at least in the case of ATG7 (Lee et al, 2012). Interestingly, p62 itself has been ascribed with potentially oncogenic functions, including a key role in the transduction of RAS-elicited signals as well as in the activation of a feedforward loop involving the cytoprotective transcription factor NF-xB driven by oncogenic stress (Duran et al, 2008; Mathew et al, 2009; Takamura et al, 2011; Ling et al, 2012). Autophagy may therefore inhibit oncogenesis by limiting p62 availability (Mathew et al, 2009), at least in some settings.

The t(9;22)(q34;q11) translocation is found in about 90% of chronic myeloid leukemia patients, resulting in the synthesis of a fusion protein that involves breakpoint cluster region (BCR) and ABL proto-oncogene 1 (ABL1) (Ben-Neriah et al, 1986). BCR-ABL1 is a constitutively active kinase and is etiologically involved in leukemogenesis, as demonstrated by the outstanding clinical success of imatinib mesylate, a BCR-ABL1-targeting kinase inhibitor (Druker et al, 2001). Arsenic trioxide, a chemotherapeutic agent commonly employed against various forms of leukemia, appears to trigger the p62-dependent and cathepsin B-dependent degradation of BCR-ABL1 in leukemic progenitors (Goussietis et al, 2012). In line with this notion, the pharmacological or genetic inhibition of autophagy or cathepsin B reportedly limits the antileukemic potential of arsenic trioxide (Goussietis et al, 2012). The t(15;17)(q22;q21) translocation can be documented in 95% of promyelocytic leukemia cases, resulting in the expression of a chimera that involves promyelocytic leukemia (PML) and retinoic acid receptor, alpha (RARA) (Godillard et al, 1991). PML-RARA blocks normal retinoic acid-dependent myeloid differentiation, de facto driving leukemogenesis (Rousselot et al, 1994). Patients expressing PML-RARA generally benefit from the administration of all-trans retinoic acid (ATRA), resulting in PML-RARA degradation and restored myeloid differentiation (Wang et al, 2011). Pharmacological and genetic evidence suggests that autophagy is implicated in both ATRA- and arsenic trioxide-driven PML-RARA degradation (Isakson et al, 2010; Wang et al, 2011). Further experimentation is required to understand whether autophagy degrades potentially oncogenic proteins in cells not exposed to chemotherapeutic agents.

Autophagy is implicated in innate responses that prevent the establishment and proliferation of malignant cells (Ma et al, 2013). At least in some circumstances, dying malignant cells are capable of recruiting antigen-presenting cells (APCs) and other cellular components of the immune system, resulting in the elicitation of innate and/or adaptive antitumor immune responses (Deretic et al, 2013; Kroemer et al, 2013). On the one hand, autophagic responses are required for dying neoplastic cells to release ATP in optimal amounts, which not only recruits APCs through purinergic receptor P2Y, G-protein coupled, 2 (P2RY2), but also activates them to release immunostimulatory chemokines through purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7) (Michaud et al, 2011). On the other hand, autophagy in immune cells is implicated in several steps of both adaptive and innate immune responses (Ma et al, 2013). Thus, both cancer cell-intrinscic and systemic defects in autophagy may prevent the host immune system to properly recognize and eliminate pre-malignant and malignant cells.

Autophagy mediates potent anti-inflammatory effects (Deretic et al, 2013). At least in some cases, malignant transformation is stimulated by an inflammatory microenvironment, which contains high amounts of potentially genotoxic ROS as well as various mitogenic cytokines (Coussens et al, 2013). Proficient autophagic responses limit inflammation as: (1) they efficiently dispose of the so-called inflammasomes (the supramolecular platforms that are responsible for the maturation and secretion of pro-inflammatory interleukin-1β and interleukin-18), as well as damaged mitochondria, which would otherwise release endogenous inflammasome activators (Nakahira et al, 2011; Zitvogel et al, 2012); (2) they are linked to the inhibition of pro-inflammatory signals delivered by some pattern recognition receptors, such as RIG-I-like receptors (Journai et al, 2007); (3) they limit the abundance of B-cell CLL/lymphoma 10 (BCL10), a protein involved in pro-inflammatory NF-xB signaling (Paul et al, 2012); (4) they are connected to the inhibition of transmembrane protein 173 (TM173, best known as STING), a pattern recognition receptor involved in the delivery of pro-inflammatory cues in response to cytosolic nucleic acids (Saitoh et al, 2009).

Finally, autophagy may suppress carcinogenesis owing to its key role in the first line of defense against viral and bacterial infection (Deretic et al, 2013). Indeed, several potentially carcinogenic pathogens potently activate autophagy upon infection. These pathogens include hepatitis B virus (which promotes hepatocellular carcinoma), human herpesvirus 8 (which causes Kaposi’s sarcoma and contributes to the pathogenesis of primary effusion lymphoma and multicentric Castleman’s disease), human papillomavirus type 16 and 18 (HPV-16 and HPV-18, which cause cervical carcinoma), Epstein–Barr virus and Helicobacter pylori (both of which are associated with gastric carcinoma), Streptococcus bovis (which causes colorectal carcinoma), Salmonella enterica (which is associated with an increased incidence of Crohn’s disease, hence sustaining colorectal carcinogenesis, and gallbladder carcinoma), as well as Chlamydia pneumoniae (an etiological determinant in some forms of lung cancer) (Nakagawa et al, 2004; Travassos et al, 2010; Yasir et al, 2011; Conway et al, 2013; Griffin et al, 2013; Zhang et al, 2014). Such a xenophagic response is required for the rapid clearance of intracellular pathogens as well as for the stimulation of pathogen-specific immune responses (Deretic et al, 2013; Ma et al, 2013). Accordingly, epithelial cells bearing molecular defects in the autophagic machinery, such as those provoked by Crohn’s disease-associated point mutations in ATG16L1 and nucleotide-binding oligomerization domain containing 2 (NOD2) (Lassen et al, 2014), are more susceptible to infection by intracellular pathogens than their wild-type counterparts. In line with this notion, reduced levels of autophagic markers including BECN1 have recently been correlated with HPV-16 and HPV-18 infection in a cohort of cervical
carcinoma patients (Wang et al., 2014). Thus, autophagy may exert oncosuppressive effects also by virtue of its antiviral and antibacterial activity.

Taken together, these observations suggest that autophagy prevents malignant transformation by preserving both cellular and organismal homeostasis in conditions that pose a risk for oncogenesis (Fig 2).

Oncoproteins, oncosuppressor proteins and autophagy

In agreement with the oncosuppressive activity of autophagy, several oncoproteins, that is, proteins that drive malignant transformation upon overexpression- or mutation-dependent hyperactivation, inhibit autophagic responses (Maiuri et al., 2009). Along similar lines, many bona fide oncosuppressor proteins, that is,
proteins that are inactivated or lost in the course of oncogenesis, stimulate autophagy (Morselli et al., 2011) (Table 1).

Oncoproteins

BECN1 is inhibited upon sequestration by several members of the Bcl-2 protein family, including B-cell CLL/lymphoma 2 (BCL2) and BCL2-like 1 (BCL2L1, best known as BCL-Xs) (Pattingle et al., 2005; Mauri et al., 2007b). These proteins are overexpressed by a wide variety of hematological and solid tumors, an event that consistently reduces the sensitivity of neoplastic cells to lethal cues of either cell-intrinsic or environmental origin (Kang & Reynolds, 2009; Anderson et al., 2014). Besides inhibiting BECN1, BCL-Xs (but not BCL2) also suppresses the ability of phosphoglycerate mutase family member 5 (PGAMS) to dephosphorylate FUN14 domain containing 1 (FUNDCl) on S13, hence suppressing mitophagy (Wu et al., 2014). Interestingly, the robust oncogenic activity of Bcl-2 proteins may also reflect their metabolic and autophagy-inhibitory activity (Pattingle & Levine, 2006; Oh et al., 2011; Wei et al., 2013; Green et al., 2014).

Various oncoproteins stimulate malignant transformation by virtue of their ability to inactivate TP53. These include the human protein MDM2, which is overexpressed by a wide panel of human tumors as a result of gene amplification (Oliner et al., 1992), as well as the early HPV-16 protein E6, which is etiologically involved in the pathogenesis of human cervical carcinoma (de Freitas et al., 2014). Both MDM2 and E6 operate as E3 ligases and target TP53 to proteasomal degradation (Hock & Vousden, 2014), hence suppressing its ability to promote autophagy (and regulated cell death) in response to stress (Vousden & Lane, 2007; Hanning et al., 2013; Pietrocyla et al., 2013). Also E7, another early HPV-16 gene product that is required for viral carcinogenesis because it inhibits the oncosuppressor protein retinoblastoma 1 (RB1) (Dyson et al., 1989), has been shown to suppress autophagic responses (Hanning et al., 2013). The ability of E7 to inhibit RB1 may explain its autophagy-suppressing functions, at least in specific settings (see below) (Jiang et al., 2010).

A consistent fraction of human neoplasms is characterized by the hyperactivation of receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (erbB2, best known as HER2) or downstream signal transducers, including SRC, v-akt murine thymoma viral oncogene homolog 1 (AKT1), class I phosphatidylinositol 3-kinases (PI3Ks) and phosphoinositide-dependent protein kinase 1 (PDPK1) (Slamon et al., 1987; Irey et al., 1999; Shayeesteh et al., 1999; Ma et al., 2000; Paez et al., 2004; Stephens et al., 2004; Carpten et al., 2007; Sen & Johnson, 2011; Chinen et al., 2014). According to current views, this promotes neoplastic transformation because it allows cells to proliferate in the absence of growth factors and it increases their resistance to adverse microenvironmental conditions (Manning & Cantley, 2007; Laplante & Sabatini, 2012). In addition, the signal transduction cascades elicited by RTKs often impinge, either directly or upon the engagement of additional signaling modules, on the activation of MTORCl, de facto inhibiting autophagy (Laplante & Sabatini, 2012; Lozy et al., 2014). Of note, AKT1 reportedly suppresses autophagic responses not only by catalyzing the inactivating phosphorylation of the MTOR-repressing tumor sclerosis (TSC) complex, but also by phosphorylating and hence inhibiting BECN1 (Wang et al., 2012a), and perhaps by promoting the ability of TP53 to block autophagy in baseline or near-to-baseline conditions via a X-linked inhibitor of apoptosis (XIAP)- and MDM2-dependent signal transduction cascade (Huang et al., 2013). In line with this notion, although XIAP does not behave as a conventional oncoprotein, several human neoplasms express increased XIAP levels (Schimmer et al., 2006). Moreover, SRC not only suppresses autophagic responses by activating MTORCl via the PI3K\PDPK1 AKT1 signaling module (Laplante & Sabatini, 2012), but also inhibits mitophagy by catalyzing the inactivating phosphorylation of FUNDCl on Y18 (Liu et al., 2012b). Finally, some RTKs such as EGFR inhibit autophagy in an MTORCl-independent manner, by catalyzing the inactivating phosphorylation of BECN1 on tyrosine residues (Wei et al., 2013).

At least three members of the RAS GTAPase family, that is, Harvey rat sarcoma viral oncogene homolog (HRAS), Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), are etiologically involved in several paradigms of malignant transformation, either as a result of somatic mutations or upon the hyperactivation of upstream signal transducers (including RTKs) (Shaw & Cantley, 2006). Besides delivering robust mitogenic signals, hyperactivated RAS engages the PI3K\PDPK1 AKT1 signaling cascade, hence potently suppressing autophagic responses (in both mammals and Drosophila) (Furuta et al., 2004; Denton et al., 2012a; Laplante & Sabatini, 2012). However, RAS also transactivates p62 through NF-xB, hence igniting a p62-dependent feedforward signaling loop with pro-autophagic and oncogenic effects accompanied by sustained NF-xB activation (Duran et al., 2008; Ling et al., 2012). Along similar lines, RAS activates mitogen-activated protein kinase 8 (MAPK8, best known as JNK1) and nuclear factor, erythroid 2-like 2 (NFE2L2, best known as NRF2), thereby promoting autophagy via the JNK1-dependent phosphorylation of BCL2 (and the consequent derepression of BECN1), and the NRF2-dependent transactivation of genes encoding several autophagy receptors, including p62 and calcium binding and coiled-coil domain 2 (CALCOCO2, best known as NDP52) (Wei et al., 2008; Jain et al., 2010; DeNicola et al., 2011; Lock et al., 2011; Jo et al., 2014). Interestingly, the oncogene-driven activation of NRF2 may engage a pro-autophagic feedforward loop, stemming from the autophagy-dependent degradation of kelch-like ECH-associated protein 1 (KEAP1, the major negative regulator of NRF2) (Taguchi et al., 2012; Bae et al., 2013), as well as from the NRF2-activating phosphorylation of p62 (Inami et al., 2011; Ichimura et al., 2013). Autophagic responses are indeed recovered along with tumor progression in various models of KRAS-driven oncogenesis (see below) (Guo et al., 2013a; Rosenfeldt et al., 2013; Rao et al., 2014). Another member of the RAS family, that is, Ras homolog enriched in brain (RHEB), is often overexpressed due to genetic amplification in human prostate carcinoma (Nardella et al., 2008). RHEB suppresses autophagy as it operates as a direct activator of MTORCl downstream of AKT1 (Inoki et al., 2003; Nardella et al., 2008).

Hyperactivating mutations in B-Raf proto-oncogene, serine/threonine kinase (BRAF), in particular the C1799T substitution (generating BRAFV600E), are a common finding in biopsies from human melanoma patients (Davies et al., 2002) and have recently been associated with various forms of histiocytosis (a pseudomalignant condition affecting macrophages and dendritic cells) (Berres et al., 2014; Hervier et al., 2014). At odds with its wild-type counterpart, BRAFV600E engages the mitogenic MAPK\ERK signaling pathway
Table 1. Oncoproteins, oncosuppressor proteins and autophagy.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Function(s)</th>
<th>Link(s) to cancer</th>
<th>Link(s) to autophagy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncoproteins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKT1</td>
<td>Serine/threonine kinase</td>
<td>Hyperactivated or overexpressed in various neoplasms</td>
<td>Inhibits BECN1 and activates MTORCI</td>
<td>Carpenten et al (2007); Laplante &amp; Sabatini (2012); Wang et al (2012a); Huang et al (2013)</td>
</tr>
<tr>
<td>E7</td>
<td>RB1 inhibitor</td>
<td>Etiological factor in HPV-associated cancers</td>
<td>Suppresses autophagy, perhaps as a result of RB1 inhibition</td>
<td>Jiang et al (2010); Hanning et al (2013); de Freitas et al (2014)</td>
</tr>
<tr>
<td>HRAS</td>
<td>Small GTP-binding proteins</td>
<td>Hyperactivated or overexpressed in various neoplasms</td>
<td>Activate MTORCI via PI3K signaling</td>
<td>Furuta et al (2004); Shaw &amp; Cantley (2006); Wei et al (2008); DeNicola et al (2011); Laplante &amp; Sabatini (2012)</td>
</tr>
<tr>
<td>K Ras</td>
<td></td>
<td></td>
<td>Derepress BECN1 upon the JNK1-mediated phosphorylation of BCL2</td>
<td></td>
</tr>
<tr>
<td>NRAS</td>
<td></td>
<td></td>
<td>Promote the NRF2-dependent synthesis of p62 and NDP52</td>
<td></td>
</tr>
<tr>
<td>MDM2</td>
<td>E3 ubiquitin ligase</td>
<td>Overexpressed in various neoplasms</td>
<td>Inhibits TP53</td>
<td>Olner et al (1992); Hock &amp; Vousden (2014)</td>
</tr>
<tr>
<td>MYCL</td>
<td></td>
<td></td>
<td>Transactivate MAPK8, coding for the BECN1 derepressor JNK1</td>
<td></td>
</tr>
<tr>
<td>MYCN</td>
<td></td>
<td></td>
<td>Truncated MYC promotes autophagy independent of transcription</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MYC hyperactivation promotes ER stress, in turn triggering autophagy</td>
<td></td>
</tr>
<tr>
<td>PDK1</td>
<td>Serine/threonine kinase</td>
<td>Hyperactivated in colorectal neoplasms</td>
<td>Activates MTORC1 via AKT1, TSC2/RHEB signaling</td>
<td>Laplante &amp; Sabatini (2012); Chinen et al (2014)</td>
</tr>
<tr>
<td>PI3K</td>
<td>Lipid kinase</td>
<td>Hyperactivated in various neoplasms</td>
<td>Activates MTORC1 via AKT1, TSC2/RHEB signaling</td>
<td>Shayesteh et al (1999); Ma et al (2000); Laplante &amp; Sabatini (2012)</td>
</tr>
</tbody>
</table>
## Table 1 (continued)

<table>
<thead>
<tr>
<th>Protein</th>
<th>Function(s)</th>
<th>Link(s) to cancer</th>
<th>Link(s) to autophagy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>RTKs</td>
<td>Tyrosine kinases</td>
<td>Hyperactivated or overexpressed in various neoplasms</td>
<td>Activate MTORCl via PI3K signaling</td>
<td>Slimon et al. (1987); Paez et al. (2004); Stephens et al. (2004); Laplante &amp; Sabatini (2012); Wei et al. (2013); Lozy et al. (2014)</td>
</tr>
<tr>
<td>SRC</td>
<td>Non-receptor tyrosine kinase</td>
<td>Hyperactivated in various cancers</td>
<td>Activates MTORCl via PI3K signaling</td>
<td>Irby et al. (1999); Sen &amp; Johnson (2011); Liu et al. (2012b)</td>
</tr>
<tr>
<td>XIAP</td>
<td>E3 ubiquitin ligase</td>
<td>Overexpressed in various tumors</td>
<td>Inhibits the autophagy-blocking activity of cytoplasmic TP53 (?)</td>
<td>Schimmer et al. (2006); Huang et al. (2013)</td>
</tr>
<tr>
<td><strong>Oncosuppressor proteins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMBRA1</td>
<td>Component of class III PI3K complex</td>
<td>Mutated in endometrial, colorectal and urinary tract neoplasms</td>
<td>Key factor for canonical autophagy</td>
<td>Codogno et al. (2012); Chianfani et al. (2015)</td>
</tr>
<tr>
<td>ATG5</td>
<td>E3 ubiquitin ligase</td>
<td>Downregulated in melanoma</td>
<td>Key factor for canonical autophagy</td>
<td>Codogno et al. (2012); Liu et al. (2013a)</td>
</tr>
<tr>
<td>BECN1</td>
<td>Component of class III PI3K complex</td>
<td>Monoallelically deleted or downregulated in various solid tumors</td>
<td>Key factor for canonical autophagy</td>
<td>Liang et al. (1999); Qu et al. (2003); Miracco et al. (2007); Codogno et al. (2012); Laddha et al. (2014)</td>
</tr>
<tr>
<td>BH3-only proteins</td>
<td>Pro-apoptotic Bcl-2 family members</td>
<td>Downregulated in various hematological and solid tumors</td>
<td>Derepress BECN1 by displacing it from BCL2 and BCL-XL</td>
<td>Ahn et al. (2007); Maiuri et al. (2007a); Maiuri et al. (2007b)</td>
</tr>
<tr>
<td>BIF1</td>
<td>Component of class III PI3K complex</td>
<td>Downregulated in colorectal carcinoma</td>
<td>UVRAG interactor</td>
<td>Takahashi et al. (2007); Coppola et al. (2008); Takahashi et al. (2013)</td>
</tr>
<tr>
<td>DAPK1</td>
<td>Serine/threonine kinase</td>
<td>Downregulated in various solid tumors</td>
<td>Derepresses BECN1 by displacing it from BCL2</td>
<td>Raveh et al. (2001); Martorati et al. (2005); Christoph et al. (2007); Zalckvar et al. (2009)</td>
</tr>
<tr>
<td>DRA53</td>
<td>GTP-binding protein</td>
<td>Downregulated in breast and ovarian carcinoma</td>
<td>Inhibits MTORCI by antagonizing PI3K signaling</td>
<td>Yu et al. (1999); Feng et al. (2008); Lu et al. (2008)</td>
</tr>
<tr>
<td>DRAM1</td>
<td>Lysosomal protein</td>
<td>Downregulated in many tumors as a result of TP53 inactivation</td>
<td>Involved in TP53-dependent autophagy</td>
<td>Crighton et al. (2006); Leroy et al. (2014)</td>
</tr>
<tr>
<td>FIP200</td>
<td>Multifunctional protein</td>
<td>Affected by truncating mutations in breast cancer</td>
<td>Component of the ULK1-ATG13-ATG101 complex</td>
<td>Chano et al. (2002); Hara et al. (2008)</td>
</tr>
<tr>
<td>FOXO1</td>
<td>Transcription factor</td>
<td>Mutated in DLBCL</td>
<td>Interacts with ATG7 in the course of stress-induced autophagy</td>
<td>Huang et al. (2005); Zhao et al. (2010)</td>
</tr>
<tr>
<td>LKB1</td>
<td>Serine/threonine kinase</td>
<td>Germline mutations cause Peutz–Jeghers’s syndrome</td>
<td>Activates the TSC complex via AMPK</td>
<td>Hemminki et al. (1998); Shaw et al. (2004); Ji et al. (2007)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mutated in a proportion of SCCs and lung carcinomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NF1</td>
<td>GTPase</td>
<td>Germline mutations cause type I neurofibromatosis</td>
<td>Activates the TSC complex by antagonizing RAS signaling</td>
<td>Fountain et al. (1989); Xu et al. (1990); Johannessen et al. (2005)</td>
</tr>
</tbody>
</table>
Table 1 (continued)

<table>
<thead>
<tr>
<th>Protein</th>
<th>Function(s)</th>
<th>Link(s) to cancer</th>
<th>Link(s) to autophagy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>p19ARF</td>
<td>MDM2 inhibitor</td>
<td>Mutated or deleted in several hematological and solid tumor</td>
<td>Stimulates autophagy via TP53-dependent and -independent mechanisms</td>
<td>Faderi et al (1999); Abida &amp; Gu (2008); Pimkina et al (2009)</td>
</tr>
<tr>
<td>smARF</td>
<td>Alternative CDKN2A product</td>
<td>Mutated or deleted in several hematological and solid tumors</td>
<td>Derepresses BECN1 by displacing it from BCL-XL</td>
<td>Faderi et al (1999); Reef et al (2006); Pimkina et al (2009)</td>
</tr>
<tr>
<td>TSC1</td>
<td>GTPases</td>
<td>Germline mutations cause TSC</td>
<td>The TSC complex inhibits mTORC1 via RHEB</td>
<td>van Sligtenhorst et al (1997); Inoki et al (2002)</td>
</tr>
<tr>
<td>UVRAG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**AKT1, v-ale murine thymoma viral oncogene homolog 1; AMBRA1, autophagy/beclin-1 regulator; AMPK, 5′-AMP-activated protein kinase; BCL2, B-cell CLL/lymphoma 2; BECN1, Beclin 1; BNIP3, BCL2 adenovirus E1B 19 KDa interacting protein 3; BNIP3L, BNIP3-like; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CDKN2A, cyclin-dependent kinase inhibitor 2A; DAPK1, death-associated protein kinase 1; DIRAS3, DIRAS family, GTP-binding RAS-like 3; DRAM1, DNA-damage regulated autophagy modulator 1; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; FOXO1, forkhead box O1; FUNDC1, FUN14 domain containing 1; HIF-1, hypoxia-inducible factor 1; HPV, human papillomavirus; HRAS, Harvey rat sarcoma viral oncogene homolog; KRAS, Kirsten rat sarcoma viral oncogene homolog; mTORC1, mechanistic target of rapamycin complex 1; MYC, v-myc avian myelocytomatosis viral oncogene homolog; MYCN, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; NF1, neurofibromin 1; Nras, neuroblastoma RAS viral (v-ras) oncogene homolog; PDPK1, phosphoinositide-dependent protein kinase 1; PHTS, PTEN hamartoma tumor syndrome; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog; RB1, retinoblastoma 1; RCC, renal cell carcinoma; RHEB, Ras homolog enriched in brain; RTK, receptor tyrosine kinase; SCC, squamous cell carcinoma; TSC2, tuberous sclerosis complex 2; TRPM3, transient receptor potential nonselective cation channel subfamily M, member 3; TSC, tuberous sclerosis; ULK1, unc-51-like autophagy-activating kinase 1; UVRAG, UV radiation resistance associated; VHL, von Hippel–Lindau tumor suppressor; XIAP, X-linked inhibitor of apoptosis.**

even in the absence of RTK-emanated and RAS-transduced signals, *de facto* rendering cell proliferation independent of extracellular growth factor availability (Sharma et al, 2006). Activated ERK phosphorylates TSC2, hence inhibiting autophagy as a consequence of mTORC1 activation (Ma et al, 2005). In addition, constitutive signaling via the BRAF axis results in a chronic state of ER stress that triggers an adaptive autophagic response required for the survival of transformed cells and, at least in some settings, sustaining their resistance to pharmacological BRAF inhibitors (Corazzari et al, 2014; Ma et al, 2014). This may explain, at least in part, the sensitivity of established BRAF V600E-driven lung adenocarcinomas to the deletion of Atg7 (see below) (Strohecker et al, 2013).

**v-myc avian myelocytomatosis viral oncogene homolog (MYC), v-myc avian myelocytomatosis viral oncogene lung carcinoma- derived homolog (MYCL) and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) are the major effectors of the mitogenic MAPK/ERK signal transduction cascade (Dang, 2012). MYC, MYCL and MYCN are affected by various mutational events in a wide panel of human malignancies (Dang, 2012). These include point mutations as well as larger genetic rearrangements such as the t(8;14)(q24;q32) translocation, which is etiologically associated with Burkitt’s lymphoma (Dalla-Favera et al, 1982). Besides overriding the microenvironmental control on proliferation, the hyperactivation of MYC family members has been**
linked to suppressed autophagy as a consequence of eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1, best known as 4EBP1) overexpression (Balakumaran et al., 2009). Apparently at odds with this notion, MYC depletion reportedly inhibits the formation of autophagosomes, possibly as a consequence of reduced JNK1 expression and consequent BCL2 phosphorylation (Toh et al., 2013). In addition, MYC-driven oncogenesis resembles its BRAF-driven counterparts in that it causes a chronic condition of ER stress that ensues, rather than accompanies, transformation (Hart et al., 2012). Moreover, it seems that colorectal cancer cells exposed to nutrient deprivation and hypoxia accumulate a transcriptionally inactive, cytoplasmic, calpain-derived cleavage product of MYC that not only supports their survival by triggering autophagy, but also favors other facets of tumor progression, including anchorage-independent growth and genomic instability (Conacci-Sorrell et al., 2014).

In summary, the net effect of RAS hyperactivation and its consequences on autophagy exhibit (at least some degree of) context dependency. This apparent discrepancy may reflect the presence/absence of genetic abnormalities other than the activation of a single oncogene. Irrespective of this hitherto unexplored possibility, autophagy appears to be restored and to be required for optimal tumor progression in rodent models of KRAS-, BRAF- and MYC-driven oncogenesis, perhaps as a compensatory response to oncogenic stress that ensues, rather than accompanies, transformation (Guo et al., 2013a; Rosenfeldt et al., 2013; Strohecker et al., 2013; Conacci-Sorrell et al., 2014; Rao et al., 2014). The molecular mechanisms that are responsible for the reconstitution of autophagic responses in these settings have not yet been elucidated.

Oncosuppressor proteins

The Li–Fraumeni syndrome, a dominantly inherited disorder characterized by the early-onset of various tumors (including bone and soft tissue sarcomas, breast carcinomas, brain cancers and acute leukemias), is caused by germline mutations in TP53 (Malkin et al., 1990; McBride et al., 2014). Moreover, the TP53 system is inactivated as a consequence of somatic mutations or genetic/epigenetic effects affecting its regulators, such as MDM2 (see above), in more than 50% of sporadic human malignancies (Leroy et al., 2014). Besides engaging the cell death machinery in cells bearing irreparable molecular defects (mainly DNA damage), via transcriptional as well as transcription-independent mechanisms (Moll et al., 2005; Riley et al., 2008), stress-stabilized TP53 can transactivate various genes involved in autophagic responses (Maiuri et al., 2010; Pietrocola et al., 2013). These include, but are not limited to, the genes coding for the β1 and β2 subunits of AMPK (i.e., PRKAB1, PRKAB2) (Feng et al., 2007), the gene coding for the AMPK activators sestrin 1 (i.e., SESN1) and SESN2 (Budanov et al., 2004; Budanov & Karin, 2008), genes encoding various BH3-only proteins (i.e., BAD, BNIP3) and death-associated protein kinase 1 (i.e., DAPK1), all of which stimulate autophagy by favoring the displacement of BECN1 from inhibitory interactions with BCL2 and BCL-XL (Mortari et al., 2005; Feng et al., 2007; Maiuri et al., 2007a; Maiuri et al., 2007b; Zalcikar et al., 2009), as well as the gene coding for DNA-damage-regulated autophagy modulator 1 (i.e., DRAM1), a lysosomal protein that sustains TP53-dependent autophagic responses via an unknown mechanism (Crighton et al., 2006). The gene coding for the upstream activator of TP53 p19ARF (i.e., CDKN2A) is also mutated or lost in several solid and hematological malignancies (Faderl et al., 1999). Full-length p19ARF promotes autophagy via TP53- as well as TP53-independent mechanisms (Abida & Gu, 2008). Moreover, a short mitochondrial isoform of p19ARF commonly known as smARF stimulates autophagic responses by displacing BECN1 from BCL-XL (Reef et al., 2006). Interestingly, at least part of the autophagy-promoting functions of DAPK1 may result from its ability to initiate a potentially self-amplifying p19ARFTP53 signal transduction cascade (Raveh et al., 2001; Martorati et al., 2005).

The gene encoding BECN1, which is required for canonical autophagy (Liang et al., 1999; Codogno et al., 2012), maps to a tumor susceptibility locus on chromosome 17q21 that is monoallelically deleted in a high proportion of sporadic breast and ovarian carcinomas (Aita et al., 1999). Moreover, the expression levels of BECN1 are reduced in a panel of human neoplasms, including brain tumors as well as gastric and colorectal carcinomas (Rubinsztein et al., 2012). Often, BECN1 is co-deleted with breast cancer 1, early onset (BRCA1), a well-known oncosuppressor gene whose loss is associated with familial forms of breast and ovarian carcinoma (Futreal et al., 1994). This has recently led some investigators to propose that the loss of BECN1 does not etiologically contribute to oncogenesis (Laddha et al., 2014). However, in two large, independent cohorts of breast carcinoma patients, reduced levels of BECN1-coding, but not BRCA1-coding, mRNA have been associated with several adverse prognostic features, including estrogen receptor negativity, HER2 overexpression, basal phenotype, TP53 mutations, and advanced tumor grade, as well as with decreased patient survival (Tang et al., 2015).

Further corroborating the notion that BECN1 constitutes a haploinsufficient oncosuppressor protein (Yue et al., 2003), various physical and functional activators of BECN1 have been ascribed with tumor-suppressive functions. The expression of DAPK1, smARF and several BH3-only proteins is lost or reduced as a result of genetic or epigenetic alterations in human tumors of distinct histological origin (Faderl et al., 1999; Christoph et al., 2007). Along similar lines, AMBRA1 is mutated in a subset of endometrial, colorectal and urinary tract neoplasms (Cianfanelli et al., 2015), the gene coding for the BECN1 activator UV radiation resistance associated (UVRAG) is monoallelically mutated in a high proportion of gastric and colonic tumors (Liang et al., 2006; Kim et al., 2008), and the expression of SH3-domain GRB2-like endophilin B1 (SH3GLB1, a positive modulator of UVRAG best known as BIF1) (Takahashi et al., 2007), is reduced in colorectal carcinomas (Takahashi et al., 2007; Coppola et al., 2008). Thus, the BECN1 system appears to be negatively regulated in the course of several paradigms of malignant transformation. As an exception to this trend, the BECN1+/− genotype delays, rather than accelerates, lymphoid oncogenesis in mice lacking the ATM serine/threonine kinase (Valentin-Vega et al., 2012). Perhaps, such an oncogenic function of BECN1 reflects the accrued dependency of Atm−/− cells on mitochondrial respiration and role of autophagy in the maintenance of a functional mitochondrial network. Of note, BECN1 and several of its interactors, including UVRAG and VPS34, are also involved in the late steps of endocytosis (McKnight et al., 2014). Moreover, UVRAG contributes to genomic stability in an autophagy-unrelated manner (Zhao et al., 2012). Finally, the oncosuppressive functions of AMBRA1 appear to stem, at least in part, from its ability to promote the dephosphorylation-dependent degradation of MYC (Cianfanelli et al., 2015). Thus, the impact of the BECN1 system on oncogenesis and tumor progression may be independent of autophagy, at least in some settings.
Germline mutations in RB1 cause a heritable form of retinoblastoma, a rapidly developing cancer that develops from immature retinal cells (Friend et al., 1986). Sporadic RB1 mutations have been detected in a wide spectrum of neoplasms including osteosarcomas, small cell lung carcinomas and breast carcinomas (Cryns et al., 1994). RB1 is well known for its ability to inhibit various members of the E2F transcription factor family, hence preventing cell cycle progression in the absence of growth factors. The actual role of E2F proteins in autophagic responses, however, remains unclear. On the one hand, the inhibition of E2F by RB1 has also been linked to the activation of autophagy (Jiang et al., 2010), perhaps as a result of declining levels of BCL2 and consequent BECN1 derepression (Gomez-Manzano et al., 2001). On the other hand, E2F1 has been shown to promote the synthesis of various components of the autophagic machinery, including ATG1, ATG5 and LC3 (Polager et al., 2008). Thus, the ability of E2F family members to regulate autophagy may show some degree of context-dependency.

A panel of genetic conditions characterized by an increased risk of breast, thyroid and endometrial tumors cumulatively referred to as PTEN hamartoma tumor syndrome (PHTS) is provoked by germline mutations in phosphatase and tensin homolog (PTEN), an enzyme that promotes autophagy by functionally antagonizing PI3K signaling (Liaw et al., 1997; Marsh et al., 1997; Arico et al., 2001). Moreover, the inactivation of PTEN as a result of sporadic mutations is very common among human cancers (Sansal & Sellers, 2004). DIRAS family, GTP-binding Ras-like 3 (DIRAS3), another functional antagonist of PI3K with pro-autophagic activity (Lu et al., 2008), is frequently underexpressed in breast and ovarian carcinoma upon loss of heterozygosity or promoter hypermethylation (Yu et al., 1999; Feng et al., 2008).

Germline mutations in neurofibromin 1 (NF1), serine threonine kinase 11 (STK11), TSC1 and TSC2 are also associated with syndromes characterized by an increased incidence of both benign and malignant neoplasms, notably, type I neurofibromatosis (NF1), Peutz–Jeghers’s syndrome (STK11) and tuberous sclerosis (TSC1 and TSC2) (Fountain et al., 1989; van Slegtenhorst et al., 1997; Hemminki et al., 1998). Moreover, somatic mutations in STK11 have been documented in a considerable percentage of squamous cell carcinomas and lung adenocarcinomas (Ji et al., 2007). As a common denominator, the inactivation of NF1 (an upstream inhibitor of RAS), STK11 (an activator of AMPK best known as LKB1), TSC1 or TSC2 promotes MTORC1 signaling, hence stimulating cell proliferation and inhibiting autophagic responses (Xu et al., 1990; Inoki et al., 2002; Shaw et al., 2004; Johannessen et al., 2005). In spite of such an MTORC1-dependent inhibition of autophagy, the monoallelic loss of Beclin1 suppresses spontaneous renal tumorigenesis in Tsc2−/− mice (Parkhitko et al., 2011). This may indicate that the Tsc2−/− genotype does not completely block autophagic responses, or that—at least in this model—BECN1 exerts oncosuppressive functions that are mainly autophagy-independent. The deletion of Rb1c1 has also been shown to suppress, rather than enhance, mammary tumorigenesis driven by the polyoma middle T antigen (PyMT) (Hara et al., 2008; Wei et al., 2011). Although in this setting the absence of FIP200 was indeed associated with autophagic defects in PyMT-expressing malignant cells, such alterations were not etiologically linked to oncogenesis. This is intriguing as FIP200 (which is also involved in the regulation of RB1) is considered as a classical oncosuppressor protein and is lost as a consequence of large deletions in a high fraction of breast carcinomas (Chano et al., 2002).

The von Hippel–Lindau syndrome, an inherited disorder characterized by the formation of tumors and cysts at various anatomical locations, is provoked by germline mutations in von Hippel–Lindau tumor suppressor, E3 ubiquitin protein ligase (VHL) (Seizinger et al., 1988). Moreover, VHL is affected by somatic mutations in a large proportion of renal cell carcinomas (Shuin et al., 1994). In VHL-deficient cells, hypoxia-inducible factor 1 (HIF-1) accumulates irrespective of oxygen concentration (because VHL normally targets it to proteasomal degradation), resulting in the transactivation of genes involved in bioenergetic metabolism and angiogenesis (Maxwell et al., 1999). VHL suppresses autophagy by an epigenetic mechanism involving miR-204 (Mikhaylova et al., 2012; Hall et al., 2014). MiR-204 targets LC3B as well as transient receptor potential cation channel, subfamily M, member 3 (TRPM3), a Ca2+- and Zn2+-conductive channel that potently stimulates autophagy. Moreover, the hyperactivation of HIF-1 supports mitophagy upon the upregulation of BCL2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) and BNIP3-like (BNIP3L) even in normoxic conditions (Tracy et al., 2007; Zhang et al., 2008; Bellot et al., 2009; Wilkinson et al., 2009). Thus, the loss of VHL may sustain tumor progression not only as it promotes angiogenesis, but also as it stimulates autophagy. Of note, HIF-1 is not a bona fide oncoprotein, yet multiple cancer cells express increased HIF-1 levels and rely on HIF-1 for survival (Luo et al., 2009).

The transcription factor forkhead box O1 (FOXO1) is mutated in a percentage of diffuse large B-cell lymphoma (DLBCL) cases and is etiologically involved in at least one model of murine oncogenesis (Huang et al., 2005). FOXO1 is classically ascribed with oncosuppressive functions by virtue of its multipronged pro-apoptotic activity (Fu & Tindall, 2008). In addition, a cytosolic pool of FOXO1 seems to be required for stress-induced autophagy as a consequence of its physical interaction with ATG7 (Zhao et al., 2010). Along similar lines, ATG5 is expressed at low levels in primary melanomas as compared to benign nevi, resulting in reduced autophagic proficiency (Liu et al., 2013a), and its absence favors oncogenesis in mice (Takamura et al., 2011). Although neither FOXO1 nor ATG5 can be considered as bona fide oncoproteins, these results support the contention that various factors with oncosuppressive functions promote autophagic responses.

Taken together, the observations presented above indicate that the hyperactivation of oncoproteins, as well the inactivation of oncosuppressor proteins, most often limits autophagic responses and that the partial suppression of autophagy underlies several (though perhaps not all) paradigms of oncogenesis. The actual impact of primary oncogenic events on autophagy, however, may be influenced (at least to some extent) by the presence/absence of additional genetic defects, and hence is likely to evolve along with tumor progression.

Autophagy and tumor progression

Autophagic responses generally support the growth and progression of established tumors by reducing their sensitivity to cell-intrinsic as well as microenvironmental stimuli that would normally promote their demise, in particular upon the so-called epithelial-to-mesenchymal transition (Kroemer et al., 2010; Avivar-Valderas et al,
This notion is supported by a growing amount of data indicating that defects in the autophagic machinery often restrain the proliferation, dissemination and metastatic potential of malignant cells, as discussed below. Moreover, advanced human tumors generally exhibit an increased autophagic flux, correlating with an invasive/metastatic phenotype, high nuclear grade, and poor disease outcome (Lazova et al., 2012; Mikhaylova et al., 2012).

Although mice with a systemic mosaic deletion of Atg5 or a liver-specific knockout of Atg7 develop spontaneous hepatic neoplasms more frequently than their wild-type counterparts (see above), these malignancies are mostly benign (pointing to defects in tumor progression) and their size can be further decreased by the simultaneous deletion of Sqstm1 (Takamura et al., 2011). In accord with these data, p62 has been shown to support the progression of both endogenous (ERBB2-driven) and xenografted mammary tumors through a variety of mechanisms, including the activation of NRF2 (see above) (Chen et al., 2013; Cai-McRae et al., 2014). As opposed to their autophagy-competent counterparts, highly metastatic hepatocellular carcinoma cell lines infected with lentiviruses that stably downregulate BECN1 or ATG5 are virtually unable to survive within the metastatic niche, although they normally proliferate, invade...

Figure 3. Tumor-supporting functions of autophagy.
Once malignant transformation has occurred, autophagy is believed to promote tumor progression and resistance to therapy. Such tumor-supporting functions reflects the ability of autophagy to: (1) improve the resistance of cancer cells to endogenous conditions that normally provoke cell death, such as the detachment from the basal membrane, hypoxia and nutrient deprivation; (2) render transformed cells less sensitive to therapy-induced cell death; (3) sustain the survival of cancer cells that enter a state of dormancy or senescence in response to therapy; and (4) ensure the maintenance of the cancer stem cell compartment. EMT, epithelial-to-mesenchymal transition.
surrounding tissues and undergo the epithelial-to-mesenchymal transition (Peng et al., 2013). Along similar lines, the shRNA-medi-
dated downregulation of Atg5 or p62 abolishes the ability of Tsc2\(^{-/-}\) Ttrp53\(^{-/-}\) MEFs to develop macroscopic tumors upon inoculation into nude mice (Parkhitko et al., 2011). Moreover, the robust anti-
metastatic effects of N-myc downstreamregulated 1 (NDRG1) have recently been ascribed to its ability to suppress stress-induced autophagic responses (Sahni et al., 2014).

The lung-specific deletion of Atg7 during the late stages of \(\text{BRAF}^{\text{V600E}}\)-driven carcinogenesis favors the development of small oncocytomas (which are relatively benign tumors) rather than adenocarcinomas, a shift that is accompanied by the accumulation of dysfunctional mitochondria and an increased dependency on exogenous glutamine (Strohecker et al., 2013). Similar results have been obtained in models of \(\text{KRAS}^{G12D}\)-driven lung and pancreatic carcinogenesis, upon the tissue-specific deletion of Atg5 or Atg7 (Guo et al., 2013a; Rosenfeldt et al., 2013; Rao et al., 2014; Yang et al., 2014), as well as in models of breast carcinoma driven by the mammary-gland specific knockout of partner and localizer of BRCA2 (Palb2), upon the monoallelic deletion of \(\text{Becn1}\) (Huo et al., 2013). Intriguingly, the downregulation of Atg1 (the fly ortholog of ULK1) by RNA interference also suppressed a hyperproliferative eye phenotype caused in \(\text{Drosophila}\) melanogaster by the ectopic expression of \(\text{Ras}^{12V}\) (a constitutively active variant of the fly ortholog of mammalian RAS proteins) but had an opposite effect on the overgrowth of the eye epithelium provoked by mutations in the oncosuppressor gene scribbled (scrb) (Perez et al., 2014). Similarly, the individual depletion of 12 distinct components of the autophagic machinery (i.e., Atg1, Atg6, Atg12, Atg5, Atg7, Atg4a, Atg4b, Atg8a, Atg8b, Atg9, Atg10 and Atg18) promoted, rather than limited, the overgrowth of adult \(\text{Drosophila}\) eyes and their larval precursor tissues in so-called eyeful flies (a model of Notch-driven carcinogenesis) (Perez et al., 2014).

In some models of endogenous mammalian carcinogenesis, the \(\text{Trp53}^{1/-}\) genotype prevents genetic interventions that target the autophagic machinery from provoking metabolic and bioenergetic alterations that limit tumor progression (Huo et al., 2013; Rosenfeldt et al., 2013; Rao et al., 2014). Conversely, the response of pancreatic cancer cells, xenografts and \(\text{KRAS}^{G12D}\)-driven autochthonous adenocarcinomas to genetic or pharmacological autophagy inhibition persists in the context of TP53 loss-of-heterozygosity (Yang et al., 2011; Yang et al., 2014). \(\text{KRAS}^{G12D}\)-driven pancreatic adenocarcinoma cells entering a state of dormancy (rather than succumbing in response to oncogene ablation (i.e., the shutdown of oncogenic \(\text{KRAS}\) signaling) have recently been show to activate autophagy to efficiently counteract metabolic stress (Viale et al., 2014). Of note, whereas primary \(\text{KRAS}^{G12D}\)-expressing cells generally exhibit increased glucose and glutamine uptake, as well as an elevated anabolic flux via the pentose phosphate pathway (Yang et al., 2012; Rosenfeldt et al., 2013), the survival of oncogene-depleted pancreatic adenocarcinoma cells critically relies on oxidative phosphorylation (Viale et al., 2014). Thus, exposing such dormant pancreatic adenocarcinoma cells to the inhibitor of oxidative phosphorylation oligomycin reportedly abolishes their ability to form tumors upon \(\text{KRAS}^{G12D}\) re-expression (Viale et al., 2014).

Interestingly, \(\text{KRAS}^{G12D}\)-expressing pancreatic adenocarcinoma cells driven into dormancy upon oncogene ablation also display functional and phenotypic features of cancer stem cells (CSCs) (Viale et al., 2014). Moreover, mammary CSCs (which propagate in culture as mammospheres) are often characterized by an elevated autophagic flux, and their ability to efficiently form tumors \(\text{in vivo}\) appears to rely on autophagy, as tumor formation can be abolished by the genetic inhibition of \(\text{Becn1}\) or \(\text{Atg4a}\) (Gong et al., 2013; Wolf et al., 2013). Thus, autophagy may also sustain tumor progression by preserving the viability of the CSC compartment and/or by promoting the persistence of dormant cancer cells (Viale et al., 2014).

Cancer cells isolated from established tumors and subjected to the genetic or pharmacological inhibition of autophagy are less resistant to exogenous stimuli than their wild-type counterparts (Boya et al., 2005; Amaravadi et al., 2007; Kroemer et al., 2010). In line with this notion, autophagy-deficient tumors are often more sensitive to several chemotherapeutic agents as well as to radiation therapy than their autophagy-proficient counterparts (Janku et al., 2011; Ko et al., 2014; Levy et al., 2014). This does not necessarily hold true for immunocompetent mice. Indeed, autophagic responses preceding the demise of cancer cells exposed to a selected panel of agents are required (though not sufficient) for cell death to be perceived as immunogenic and hence to eliciting a therapeutically relevant immune response (Kroemer et al., 2013; Ko et al., 2014). Cancer cells exposed to therapeutic interventions can also undergo senescence (Lopez-Otin et al., 2013). Although senescent cells do not proliferate, they may support disease relapse by releasing a wide panel of pro-inflammatory and mitogenic cytokines into the micro-
environment (underlying the so-called senescence-associated secre-
tory phenotype, SASP) (Lopez-Otin et al., 2013). Interestingly, these cells are highly dependent on autophagic responses for survival, and pharmacological inhibitors of autophagy have been shown to synergize with various chemotherapeutics in experimental models of lymphoma that are susceptible to acquire the SASP in response to treatment (Young et al., 2009; Dorr et al., 2013).

Taken together, these observations suggest that autophagy supports the progression of established neoplasms through several mechanisms (Fig 3) and that pharmacological inhibitors of autophagy may exert robust antineoplastic effects, at least in some settings.

Concluding remarks

Based on the data presented above, it is tempting to speculate that the multistep process leading from a healthy tissue to a metastatic and therapy-resistant, and hence life-threatening, neoplasm involves a temporary loss of autophagic competence (or the gain of molecular functions that antagonize, at least transitorily, autophagy-
dependent oncosuppression). Initially, defects in the autophagic process might facilitate the acquisition of malignant features by healthy cells. Later on, once malignancy is established, the restora-
tion of proficient autophagic responses may be essential to support the survival, proliferation and growth of cancer cells in the presence of adverse microenvironmental conditions (Fig 4A). How proficient autophagic responses are reconstituted after an initial phase of autophagy inhibition, however, has not yet been determined. As a possibility, the genetic or epigenetic instability that characterizes progressing tumors may restore autophagy in specific cells,
rendering them able to overcome their neighboring autophagy-incompetent counterparts. Formal experimental evidence in support of this model is lacking. At least in some settings, oncogenesis and tumor progression may indeed rely on a temporary (but not a stable) loss in autophagy competence. The mechanisms underlying the restoration of proficient autophagic responses after malignant transformation remain to be elucidated. (B, C) In specific settings, oncogenesis and tumor progression may rely on a permanent loss (B) or gain (C) of autophagic proficiency.

![Figure 4](image_url)

**Figure 4. Autophagy in malignant transformation and tumor progression.**

(A) Healthy cells appear to be protected from malignant transformation by proficient autophagic responses. Conversely, autophagy promotes tumor progression and therapy resistance in a variety of models. Thus, the transition of a healthy cell toward a metastatic and therapy-insensitive neoplasm may involve a temporary (but not a stable) loss in autophagy competence. The mechanisms underlying the restoration of proficient autophagic responses after malignant transformation remain to be elucidated. (B, C) In specific settings, oncogenesis and tumor progression may rely on a permanent loss (B) or gain (C) of autophagic proficiency.

similarly, autophagy has been shown to underlie, at least in part, the therapeutic activity of some anticancer regimens (Salazar et al., 2009; Torres et al., 2011; Vara et al., 2011). Moreover, autophagy is required not only for the emission of immunostimulatory signals by malignant cells succumbing to specific anticancer agents (Kroemer et al., 2013), but also for the activation of tumor-targeting innate and adaptive immune responses (Ma et al., 2013). Efforts should therefore be focused on the identification of precise clinical scenarios in which autophagy supports, rather than counteracts, disease progression and resistance to therapy. This is particularly important not only because autophagy inhibitors may one day become part of the clinical routine, but also because most (if not all) anticancer agents that are currently employed in the clinic modulate autophagy (Kroemer et al., 2010).

Of note, the genetic inhibition of autophagy in models of mammalian carcinogenesis has near-to-invariably been achieved with the whole-body or conditional (heterozygous or homozygous) knockout of Atg5, Atg7 or Beclin1 (Guo et al., 2013a; Rosenfeldt et al., 2013; Strohecker et al., 2013; Perez et al., 2014; Rao et al., 2014; Yang et al., 2014). In other scenarios, including the loss of scribe and the eye-fish genotype in *Drosophila*, disabling autophagy by genetic means *de facto* accelerates tumor progression (Perez et al., 2014). Moreover, the antineoplastic effects of genetic and pharmacological interventions that inhibit autophagy vary in models in which the TP53 system is lost by different modalities (i.e., homozygous knockout versus loss-of-heterozygosity) (Yang et al., 2011; Huo et al., 2013; Rosenfeldt et al., 2013; Rao et al., 2014; Yang et al., 2014). Thus, the impact of autophagy on tumor progression may exhibit a significant degree of context dependency. Accordingly, recent data indicate that only tumors that are addicted to autophagy even in nutrient-rich conditions and in the absence of stressful stimuli respond to autophagy inhibitors in vivo (Maycotte et al., 2014). This suggests that only a fraction of cancer patients may benefit from the administration of autophagy inhibitors.
In experimental settings, the pharmacological inhibition of autophagy is most often realized with the administration of chloroquine (CQ) and hydroxychloroquine (HCQ), two lysosomalotropic drugs approved by the US Food and Drug Administration for the prophylactic treatment of malaria and for the management of (chronic, discoid or systemic) lupus erythematosus as well as acute or chronic rheumatoid arthritis (Rubinsztein et al., 2012). Similar to other lysosomalotropic agents, both CQ and HCQ block autophagy by inhibiting the fusion between autophagosomes with lysosomes and their degradation (Rote & Rechsteiner, 1983). Results from several Phase I–II clinical data indicate that HCQ can be safely employed at relatively high doses to improve the clinical activity of radiation therapy as well as of distinct anticancer chemotherapeutics, including temozolomide (an alkylating agent), vorinostat (a histone deacetylase inhibitor) and bortezomib (a proteasome inhibitor) (Barnard et al., 2014; Malingam et al., 2014; Rangwala et al., 2014a; Rangwala et al., 2014b; Rosenfeld et al., 2014; Vogl et al., 2014; Wolpin et al., 2014). However, the potency and specificity of HCQ and CQ are poor, and both these compounds have been shown to mediate antineoplastic effects via multiple autophagy-independent pathways, including lethal lysosomal destabilization (Boya et al., 2003; Maycotte et al., 2012) and the normalization of the tumor vasculature (Maes et al., 2014). Thus, the abundant scientific literature concluding that pharmacological inhibitors of autophagy constitute a convenient means to arrest tumor progression or sensitize malignant cells to therapy based on results obtained with CQ and HCQ only should be taken with caution. Lys05, a potent dimeric variant of CQ, is currently being characterized in preclinical tumor models (McAfee et al., 2012). Lys05, however, seems to share the limited specificity of CQ and HCQ. Small molecules that block autophagy in a highly specific manner are therefore urgently awaited. Recently, a specific VPS34 inhibitor has been developed and shown to efficiently inhibit autophagy. However, its putative antineoplastic effects may reflect the pleiotropic activity of VPS34, which is also involved in non-autophagic vesicle trafficking (Ronan et al., 2014). Finally, it will be interesting to develop molecules that inhibit autophagy in malignant cells but not in their normal counterparts, perhaps by targeting upstream signal transducers rather than downstream effectors. Proof-of-principle data in support of the therapeutic activity of such an approach in preclinical models have already been generated (Wilkinson et al., 2009). This is particularly relevant given the key contribution of autophagy to the maintenance of homeostasis in healthy cells. Indeed, at least on theoretical grounds, efficiently inhibiting autophagy in non-transformed cells may have deleterious consequences ranging from an accrued propensity to malignant transformation to overt cytotoxicity.

Intriguingly, several experimental maneuvers that increase the lifespan of model organisms as evolutionary distant as nematodes, flies and mice, including caloric restriction as well as the administration of the MTOR inhibitor rapamycin, activate autophagy (Harrison et al., 2009; Morselli et al., 2010; Madeo et al., 2014). Moreover, these interventions generally lose their lifespan-extending activity in autophagy-deficient hosts (Morselli et al., 2010; Madeo et al., 2014). However, to which extent the lifespan-prolonging effects of autophagy directly relate to its major oncosuppressive functions remains to be determined.

Recently, several studies have demonstrated that autophagy is regulated by epigenetic alterations, including histone methylation and acetylation (Artal-Martinez de Narvajas et al., 2013; Lam et al., 2013; Eisenberg et al., 2014). In addition, transcription factors other than TP53 and HIF-1, such as transcription factor EB (TFEB) and CAMP-responsive element binding protein 1 (CREB1), are intimately involved in autophagic responses (Settembre et al., 2011; Seok et al., 2014). The precise mechanisms through which cancer-associated epigenetic alterations (and/or the consequent transcriptional reprogramming) modulate autophagy have not yet been elucidated. Obtaining profound insights into this issue may pave the way to the development of novel, cancer-specific inhibitors of autophagy with therapeutic potential.

Irrespective of these incognita, autophagy stands out as key system for the maintenance of homeostasis, hence exerting a differential impact on malignant transformation and tumor progression (Box 1).

**Box 1: Reconciling the effects of autophagy on malignant transformation and tumor progression**

- Autophagy is a crucial mechanism for the maintenance of intra-cellular homeostasis, in baseline conditions as well as in response to stress.
- Autophagy has been attributed tumor-suppressive as well as tumor-promoting functions, raising doubts on the actual therapeutic value of autophagy inhibitors for cancer therapy.
- According to a growing literature, autophagy inhibits malignant transformation, that is, the conversion of a completely normal cell into a cell that can potentially form a tumor, and is required for efficient anticancer immunosurveillance.
- Conversely, autophagy often supports tumor progression, that is, the process whereby a (pre)-neoplastic cell acquires the ability to grow unrestrained locally, promote angiogenesis, undergo the epithelial-to-mesenchymal transition, reach a metastatic niche through circulation and form secondary lesions, as well as resistance to various forms of anticancer therapy.
- From a cell-centered perspective, autophagic responses near-to-invariably exert beneficial effects, but these are detrimental for the host when they occur in cells that have already initiated malignant transformation.
- In line with this notion, pharmacological inhibitors of autophagy exert antineoplastic effects against established tumors, especially in combination with other forms of therapy.
- However, highly targeted inhibitors of autophagy for use in humans are not available, and the molecules employed so far to this aim (i.e., chloroquine and hydroxychloroquine) have several, therapeutically relevant off-target effects.
- Moreover, the true impact of autophagy on oncogenesis and tumor progression may exhibit a significant degree of context dependency.
- Thus, it is critical to characterize specific neoplasms for their actual dependency on autophagy before implementing the use of autophagy inhibitors in the clinical routine.

**Acknowledgements**

GK is supported by the Ligue contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Institut National du Cancer (INCa);
Author contributions
LG, KMR and GK conceived the review. LG wrote the review, centralized and integrated comments from co-authors, conceived the figures, and revised the review upon editorial feedback. JMBSP designed the figures. FP constructed the table. All authors corrected the review and provided valuable input to obtain a consensus view.

Conflict of interest
Vassiliki Karantza is an employee of Merck Research Laboratories. All other authors declare that they have no conflict of interest.

References

Aiviv-Valderas A, Bobrovnikova-Marjon E, Alan Dj, Bardeesy N, Debnath J, Aguirre-Ghiso JA (2013) Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK. Oncogene 32: 4932–4940
Bae SH, Sung SH, Oh SY, Lim JM, Lee SK, Park YN, Lee HE, Kang D, Rhee SG (2013) Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab 17: 73–84

© 2015 The Authors


Maiuri MC, Criollo A, Tasdemir E, Vicenzo JM, Tajeddine N, Hickman JA, Geneste O, Kroemer G (2007a) BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-xL. Autophagy 3: 374–376


familial syndrome of breast cancer, sarcomas, and other neoplasms. 
Science 250: 1233 – 1238
Cell 129: 1261 – 1274
Nat Genet 16: 333 – 334
Apoptosis: 8: 200 – 212
J Exp Med 208: 455 – 467
Genes Dev 22: 2172 – 2177


